Development of targeted therapy for hepatocellular carcinoma (HCC) remains a major challenge. We have recently identified an elevated expression of the fifth subunit of COP9 signalosome (CSN5) in early HCC as compared with dysplastic stage. In the present study, we explored the possibility of CSN5 being a potential therapeutic target for HCC. Our results show that CSN5 knockdown by small-interfering (si) RNA caused a strong induction of apoptosis and inhibition of cell-cycle progression in HCC cells in vitro. The down-regulation of CSN5 was sufficient to interfere with CSN function as evidenced by the accumulation of neddylated Cullin 1 and changes in the protein levels of CSN-controlled substrates SKP2, p53, p27 and nuclear factor-jB, albeit to a different degree depending on the HCC cell line, which could account for the CSN5 knockdown phenotype. The transcriptomic analysis of CSN5 knockdown signature showed that the anti-proliferative effect was driven by a common subset of molecular alterations including downregulation of cyclin-dependent kinase 6 (CDK6) and integrin b1 (ITGB1), which were functionally interconnected with key oncogenic regulators MYC and TGFb1 involved in the control of proliferation, apoptotic cell death and HCC progression. Consistent with microarray analysis, western blotting revealed that CSN5 depletion increased phosphorylation of Smad 2/3, key mediators of TGFb1 signaling, decreased the protein levels of ITGB1, CDK6 and cyclin D1 and caused reduced expression of anti-apoptotic Bcl-2, while elevating the levels of proapoptotic Bak. A chemically modified variant of CSN5 siRNA was then selected for in vivo application based on the growth inhibitory effect and minimal induction of unwanted immune response. Systemic delivery of the CSN5 3/8 variant by stable-nucleic-acid-lipid particles significantly suppressed the tumor growth in Huh7-luc þ orthotopic xenograft model. Taken together, these results indicate that CSN5 has a pivotal role in HCC pathogenesis and maybe an attractive molecular target for systemic HCC therapy.
Development of targeted therapy for hepatocellular carcinoma (HCC) remains a major challenge. We have recently identified an elevated expression of the fifth subunit of COP9 signalosome (CSN5) in early HCC as compared with dysplastic stage. In the present study, we explored the possibility of CSN5 being a potential therapeutic target for HCC. Our results show that CSN5 knockdown by small-interfering (si) RNA caused a strong induction of apoptosis and inhibition of cell-cycle progression in HCC cells in vitro. The down-regulation of CSN5 was sufficient to interfere with CSN function as evidenced by the accumulation of neddylated Cullin 1 and changes in the protein levels of CSN-controlled substrates SKP2, p53, p27 and nuclear factor-jB, albeit to a different degree depending on the HCC cell line, which could account for the CSN5 knockdown phenotype. The transcriptomic analysis of CSN5 knockdown signature showed that the anti-proliferative effect was driven by a common subset of molecular alterations including downregulation of cyclin-dependent kinase 6 (CDK6) and integrin b1 (ITGB1), which were functionally interconnected with key oncogenic regulators MYC and TGFb1 involved in the control of proliferation, apoptotic cell death and HCC progression. Consistent with microarray analysis, western blotting revealed that CSN5 depletion increased phosphorylation of Smad 2/3, key mediators of TGFb1 signaling, decreased the protein levels of ITGB1, CDK6 and cyclin D1 and caused reduced expression of anti-apoptotic Bcl-2, while elevating the levels of proapoptotic Bak. A chemically modified variant of CSN5 siRNA was then selected for in vivo application based on the growth inhibitory effect and minimal induction of unwanted immune response. Systemic delivery of the CSN5 3/8 variant by stable-nucleic-acid-lipid particles significantly suppressed the tumor growth in Huh7-luc Introduction Hepatocellular carcinoma (HCC) is the third most lethal neoplasm causing an estimated 600 000 deaths annually due to late diagnosis underlying liver disease and lack of effective treatment options (Bruix and Sherman, 2005; Parkin et al., 2005; Llovet and Bruix, 2008; . However, recent advances in the understanding of the complex molecular pathways driving HCC indicate that the early stages of HCC development are characterized by selection of certain common traits (Thorgeirsson and Grisham, 2002) . The progressive accumulation of genomic and epigenetic alterations during the course of chronic liver disease affects numerous regulatory pathways resulting in gradual loss of differentiation (Avila et al., 2000; Okabe et al., 2001; Berasain et al., 2003) and selection of clones characterized by unrestrained proliferation and resistance to cell death (Rust and Gores, 2000; Feitelson et al., 2002; Lee and Thorgeirsson, 2004; Arsura and Cavin, 2005) . The comprehensive analysis of genomic changes during the process of hepatocarcinogenesis may reveal suitable targets for preventing and treating HCC through targeted therapy (Roberts and Gores, 2005) .
Our previous microarray analysis revealed a consistent up-regulation of fifth subunit of COP9 signalosome (CSN5) gene in the early HCC implying that CSN5 may be one of the early markers of malignant conversion (Kaposi-Novak et al., 2009) . CSN5, also known as JAB1 or COPS5, is the catalytic center of CSN, an evolutionary conserved multi-protein complex involved in the control of proteolysis via the ubiquitin proteasome pathway, transcription, protein phosphorylation and intracellular distribution (Wei et al., 2008; Chamovitz, 2009; Kato and Yoneda-Kato, 2009; Shackleford and Claret, 2010) . Although the precise molecular mechanisms remain to be elucidated, the most studied function of the CSN is the regulation of protein degradation, which occurs primarily through the removal of NEDD8 (a ubiquitin-like modifier) from cullin-RING-E3 ligases, thereby regulating ligase activity. Among the eight CSN subunits (CSN1-CSN8), CSN5 has a central role in this deneddylation activity and controls the stability of a great variety of key intracellular regulators of survival and/or apoptotic programs, such as MYC, TGFb1, MIF, c-Jun, HIF1a, p27, E2F1 and p53, and may function either as a monomer or as the fifth component of CSN complex. In addition to controlling the stability of proteins, the CSN also mediates transcriptional regulation by mechanisms that are not yet clearly defined. In particular, CSN5 seems to act as a transcriptional coactivator for MYC, which is essential for the transcriptional activation of genes involved in cell proliferation, angiogenesis and cell invasion (Claret et al., 1996; Bae et al., 2002; Adler et al., 2006) . CSN5 activities positively and negatively affect a number of pathways, including integrin signaling, cell-cycle control and apoptosis. Given the diversity of functions and a large number of effector molecules controlled by CSN5, we hypothesized that the inactivation of the overexpressed CSN5 gene could result in reestablishment of numerous anti-oncogenic programs involved in the control of cell proliferation and apoptosis, and whereby be effective as an anti-cancer strategy.
RNA interference is a cellular mechanism for silencing gene expression, which triggers a sequence-specific degradation of target mRNA (Fire et al., 1998; Elbashir et al., 2001) . The double-stranded RNA substrates are enzymatically cleaved into small-interfering (si) RNA and mediate the suppression of target gene expression through a phylogenetically conserved intrinsic pathway of multistep processes (Sijen et al., 2001; Zamore, 2001) . The mechanistic insight raised the hope that RNA interference could be harnessed for the development of new drugs targeting all classes of pathological proteins (Hannon and Rossi, 2004; Bumcrot et al., 2006) . We have previously described the development of stablenucleic-acid-lipid particles (SNALP) as an effective systemic delivery vehicle for targeting siRNA to murine and primate liver as well as solid tumors and have demonstrated robust therapeutic silencing of endogenous hepatocyte, tumor or viral gene transcripts in the absence of any measurable immune response (Jeffs et al., 2005; Morrissey et al., 2005a, b; Zimmermann et al., 2006; Judge et al., 2009) .
Here, we report that siRNA-mediated CSN5 knockdown inhibits cell-cycle progression and greatly increases the rate of apoptosis in HCC cells in vitro.
High-throughput transcriptomic analysis of CSN5 knockdown signature revealed a common subset of molecular alterations underlying the therapeutic responses, including down-regulation of TGFb1 and MYC-target genes, such as integrin b1 (ITGB1) and cyclin-dependent kinase 6 (CDK6). At the protein level, CSN5 depletion in HCC cells increased the phosphorylation of Smad2/3 and expression of Bak with a concomitant down-regulation of nuclear factor (NF)-kB, CDK6, cyclin D1 and Bcl-2, leading to apoptotic cell death. Finally, systemic delivery of the modified CSN5siRNA encapsulated in SNALP remarkably inhibited hepatic tumor growth in an orthotopic xenograft model of human liver cancer. These results demonstrate the important role for CSN5 in liver cancer progression and suggest targeting CSN5 as a promising novel tool for anti-cancer therapy.
Results
The biological effects of CSN5 knockdown in human HCC cells in vitro To address the functions of CSN5, the HCC cell lines Huh7 and HepG2 cells were transfected with three variants of CSN5-specific siRNA (CSN5-1-3) for 2 days, and efficiency of CSN5 silencing was determined by analysis of the steady-state levels of CSN5 mRNA and protein. The CSN5-2siRNA was the most effective in reducing CSN5 mRNA, and the down-regulation was correlated with a remarkable decrease in target protein (Figures 1a and b) . Consistent with these changes, CSN5-2siRNA caused a greater suppression of HCC cell growth and, therefore, was selected for further studies (Figures 1c-e) . In two examined cell lines, Huh7 and HepG2, treatment with 15 nM CSN5-2siRNA resulted in 68 and 77% growth inhibition, respectively. Transfection with negative control (NC) siRNA did not affect cell growth. The growth inhibition in CSN5-depeleted HCC cells could be attributed in part to the defective cell-cycle progression. Fluorescence-activated cell sorting (FACS) analysis revealed accumulation of G0/G1-phase cells and a concomitant decrease in the S-phase cells in both examined HCC cell lines 2 days after treatment with CSN5-2siRNA (Figure 2a) . However, the most significant effect of CSN5 knockdown was a strong induction of apoptosis as measured by an assay detecting the denatured single-stranded DNA formed in apoptotic cells but not in the necrotic cells or cells with DNA breaks (Figure 2b ). The result was reproduced in two additional HCC cell lines Huh1 and PLC/PRF/5, which showed a similar reduction in growth rate as a consequence of CSN5 silencing (Figure 2c ). These data demonstrate that siRNA-mediated knockdown of CSN5 in human HCC cells inhibit cell-cycle progression and increases predisposition to undergo apoptotic cell death.
The molecular mechanisms underlying the growth inhibitory effects of CSN5 knockdown To identify the molecular targets and common mechanisms underlying the growth inhibitory effects caused by CSN5 silencing, Huh7 and HepG2 cells were treated with either NCsiRNA or CSN5-2siRNA for 48 h and subjected to transcriptomic analysis using gene expression microarrays. In both cell lines, we achieved a strong (greater than eightfold) CSN5-specific inhibition ( Figure 3a ). The number of differentially expressed genes that displayed more than a twofold change was 768 (402 up-and 366 down-regulated genes) and 349 (127 up-and 222 down-regulated genes) in Huh7 and HepG2 cells, respectively, using permuted Bootstrap ttest (Po0.05) ( Supplementary Figures 1a and 2a) . Given involvement of CSN5 gene in liver cancer progression, we then focused on the expressions of genes functionally interconnected with its principal regulators, MYC and TGFb1. Consistent with the reported functional relationships (Wei et al., 2008; Kato and Yoneda-Kato, 2009 ), numerous genes affected by CSN5 inactivation in HCC cells were known/putative targets of MYC or TGFb1 (Supplementary Figures 1b,  c, 2b and c).
To further explore the molecular mechanisms of CSN5 response, we have generated a common CSN5 knockdown signature consisting of 127 deregulated genes ( Figure 3b . NT, no treatment; NC, negative control siRNA; 1si., CSN5-1siRNA; 2si., CSN5-2siRNA; 3si., CSN5-3siRNA.
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expressions of 12 genes, known to be associated with MYC and/or TGFb1 pathway, such as CDK6, BRCA1, ATF3, EIF2S1, SLC2A1, ITGB1, MMP11, GSN, TIMP2, platelet-derived growth factor b (PDGFb), FSTL3 and LPL, were commonly deregulated ( Figures  3c and d) . Consisting with phenotypic changes, expressions of genes that are functionally involved in proapoptotic activity and tumor suppression (ATF3, MPM11, GSN, TIMP2 and FSTL3) were up-regulated. Conversely, genes involved in anti-apoptosis, cell-cycle progression, survival and metastasis (CDK6, EIF2S1, SLC2A1, ITGB1 and LPL) were down-regulated. In particular, the cell-cycle promoting function of CDK6, which associates with cyclin D and targets the retinoblastoma protein to allow passage through the G1/Sphase restriction point, has been shown to have functional relationships with TGFb1 and MYC (Mateyak et al., 1999; Tsubari et al., 1999) .
To gain a better understanding of the molecular mechanisms linking growth suppression in HCC cells to the CSN5 deletion, we performed an extensive western blot analysis of CSN components and selected CSNcontrolled substrates. Supporting CSN5-specific inhibition on mRNA levels (Figure 3a) , we found a significant reduction only in CSN5 protein levels, while other CSN subunits (for example CSN1, CSN3 and CSN8) showed little or no change (Figure 4a ). siRNA-mediated CSN5 silencing was sufficient to disrupt the CSN complex, and induced Cullin 1 hyperneddylation, which was paralleled by a decrease in free NEDD8 (Figure 4a ). Concomitant with a loss of CSN5 function, both examined HCC cell lines showed a decrease in the protein level of SKP2, a substrate-targeting subunit of the ubiquitin ligase complex that regulates entry into Sphase by inducing the degradation of the cyclindependent kinase inhibitors p21 and p27 (Bashir et al., 2004) . Interestingly, MYC, another candidate substrate of CSN-controlled ubiquitin ligases, which could account for CSN5 knockdown phenotype, showed no obvious changes in the protein levels, while accumulation of p53 as well as p27, a target of SKP2, was found only in HepG2 cell line characterized by wild type p53, but not in the p53 mutant Huh7 cells, reflecting cell type-specific differences (Figure 4a ). However, in agreement with microarray data, and consistent with inhibition of cell-cycle progression by CSN5 inactivation (Figures 1 and 2 ), both cell lines showed reduction in protein levels of cyclin D1, CDK6 and ITGB1 involved in the control of cell-cycle progression, although the expression of cyclin E, another regulator of G1-phase, as well as CDK2 and cyclin A, implicated in S and G2/ M transition, were unaffected (Supplementary Figure 3) . In support of the microarray analysis, CSN5 silencing caused increased phosphorylation of Smad 2 and 3, key mediators in TGFb1 signaling, involved in the control of apoptotic cell death (Figure 4b ). In addition, we found a significant reduction in the NF-kB p65 level in both examined cell lines and a concomitant downregulation of anti-apoptotic Bcl-2 reflecting defective NF-kB activation in agreement with recent data linking CSN function to IkB-a regulation (Panattoni et al., 2008) . In contrast, the levels of pro-apoptotic Bak were increased suggesting that activation of TGFb1 signaling and/or inhibition of NF-kB pathway may be common mechanisms of growth inhibition and apoptotic induction following CSN5 inactivation.
Importantly, CSN5 knockdown also caused a compensatory up-regulation of PDGFb, and decreased the expression of tumor suppressor BRCA1, reflecting a complex molecular dynamics caused by targeted inactivation of a single gene. When we blocked PDGFb expression by siRNA, we found a significant reduction in survival and increased caspase-3-mediated apoptosis (Figures 4d and e) , suggesting that a combined inactivation of several putative targets can amplify the therapeutic effect of CSN5 deletion in HCC cells. Taken together, these results show that siRNA depletion of a single gene may coordinately impact diverse oncogenic pathways acting in concert to drive liver cancer progression and provide a rationale for therapeutic targeting of CSN5.
Systemic delivery of CSN5 siRNA by SNALP suppresses orthotopic liver tumor growth The next step was to validate if systemic silencing of CSN5 could suppress liver tumor growth. To prevent immune activation and enhance siRNA stability in vivo, native CSN5-2siRNA was chemically modified by selective incorporation of 2 0 -O-methyl (2 0 OMe) uridine or guanosine nucleosides into one strand of the siRNA duplex, and encapsulated into SNALP. A modified siRNA was then screened for in vivo application in terms of Huh7-luc þ cell growth and cytokine induction using murine Flt3L dendricytes isolated from mouse bone marrow. Among the variants tested, CSN5 3/8 sequence was the most effective in inhibiting tumor cell growth (about 80%) (Figure 5a ). In addition, the modified sequence caused a minimal induction of interleukin-6 as compared with the treatment with native CSN5-2siRNA, while injection of empty SNALP had little effect on interleukin-6 levels ( Figure 5b) .
To test the therapeutic efficacy of CSN5 gene targeting, we used an orthotopic mouse model of hepatocarcinoma and bioluminescence imaging as a method of monitoring the kinetics of tumor growth. Mice with liver tumors derived from Huh7-luc þ cells were randomly assigned either to treatment or control group before starting siRNA therapy (Figure 6 ). The results showed that in control group treated with SNALP-bgal478 targeting b-galactosidase, tumors grew very rapidly and at the end point of the study (28 days) occupied a significant portion of liver parenchyma. In addition, the majority of mice developed ascites 
reflecting impairment of liver function characteristic for the end stage of liver cancer disease. In striking contrast, SNALP-CSN5 3/8 effectively inhibited the hepatic tumor growth formed by Huh7-luc þ cells and significantly improved well-being of animals (Figures 6a and  b) . Consistent with this, mice receiving siRNA therapy showed a better histology with single and much smaller tumors as well as reduction in liver-to-body ratios as reflection of the reduced tumor burden (Figures 6c and  d) . These results indicate that CSN5 is an important regulator of HCC growth and may represent a promising target for systemic therapy of human HCC.
Discussion
Hepatocarcinogenesis is a multistep process driven by the accumulation of multiple genetic and epigenetic alterations (Thorgeirsson and Grisham, 2002) . Previously, we have identified MYC as one of the driver genes for malignant conversion from the dysplastic stage to early HCC (Kaposi-Novak et al., 2009) . Notably, the presence of the MYC signature significantly correlated with increased expression of CSN5, as well as with a higher overall transcription rate of genes located in the 8q chromosome region. However, the significance of CSN5 up-regulation in liver cancer has remained undetermined. In this study, we demonstrate that siRNA-mediated knockdown of CSN5 caused a consistent and strong induction of apoptotic cell death and delayed cell-cycle progression in the examined human HCC cells. These results suggest that overexpression of CSN5 may contribute to both cell survival and proliferation and thus represent a prognostic marker for malignant conversion in liver cancer. CSN5 overexpression has been also found in breast, thyroid, skin, ovarian, lung and pancreatic cancer (Sui et al., 2001; Esteva et al., 2003; Ito et al., 2003; Kouvaraki et Adler et al., 2008) , implying that CSN5 targeting may be an effective therapeutic strategy against various cancer types. Consistent with this, depletion of CSN5 has been shown to result in growth inhibition of pancreatic cell line (Fukumoto et al., 2006) . The massive apoptosis and defective cell-cycle progression in CSN5-depleted HCC cells were paralleled by coordinated dysregulation of numerous gene expression programs acting downstream of CSN5-regulated transcription factors. As shown in Figure 3 , at transcriptional level, CSN5 knockdown-mediated downregulation of CDK6, a key regulator in G1/S-phase transition, was functionally associated with both MYC and TGFb1, and correlated with the increased expression of pro-apoptotic effectors (for example activating transcription factor 3) (Kashiwakura et al., 2008) , or activator of metastasis (for example matrix metalloproteinase 11) (Brasse et al., 2010) . In this study, we also found that the decreased levels of CDK6 and cyclin D1 proteins were correlated with the activation of TGFb1 and inhibition of NF-kB pathways (Figure 4b ). These observations may provide the molecular mechanism(s) underlying the phenotypic changes triggered by siRNA silencing of CSN5 expression, such as inhibition of G1/S transition and induction of apoptosis.
Among the important findings of the study is the demonstration of high efficiency of CSN5 targeting in a mouse xenograft model of human liver cancer. The primary obstacle for therapeutic application of RNA interference is a successful delivery to targeted cell type in vivo (Pai et al., 2006; Hokaiwado et al., 2008) . The SNALP-based technology has unique technical advantages for a systemic siRNA delivery to liver (Rossi, 2006; Whitehead et al., 2009) . First, target siRNA modified and incorporated into SNALP is protected from both glomerular filtration and serum nucleases, whereby increasing the half-life of the circulating siRNA. In particular, 2 0 OMe modification of siRNA utilized in this study mediated potent silencing of target mRNA without cytokine induction, toxicity or offtarget effects associated with unmodified siRNA (Judge et al., 2005a, b) . Second, the use of SNALP technology allowed reducing the dosing regimen up to 3 mg/kg, which is 10-fold less as compared with the standard dose of siRNA without a carrier (Morrissey et al., 2005a) . In our study, treatment with a moderate dose of 2 mg/kg was sufficient for the effective suppression of liver tumor growth in vivo (Figure 6 ). Finally, SNALP-formulated target siRNA injected intravenously primarily traffics to liver and spleen with little accumulation in other organs. Although more work is needed to optimize the therapeutic dose of SNALP-target siRNA for different stages of HCC disease, our work demonstrates the potency of systemic RNA interference targeting of CSN5 without an overt toxicity in a mouse model of orthotopic transplantation of human HCC cells and suggests its clinical utility for treatment of HCC disease. UCGGUGCgc-3 0 ). For in vivo application, CSN5-2 siRNA was synthesized by Integrated DNA Technologies (Coralville, IA, USA) in a large quantity and modified by 2 0 OMe method (Judge et al., 2005a) , and then encalpsulated into SNALP using a published method (Jeffs et al., 2005) (CSN5 3/8: sense, 5 0 -GGAmUCACCAUmUACmUUmUAAGUU-3 0 ; antisense, 5 0 -CUUAAAmGUAAUGmGUmGAUCCUU-3 0 ; mU, 2 0 OMe uridine and mG, 2 0 OMe guanosine). NCsiRNA molecules that do not target any endogenous transcript were used for control experiments. Silencer NC #1 siRNA (Ambion) and SNALPformulated bgal478siRNA (Judge et al., 2005b) were used for in vitro and in vivo studies, respectively.
Cell culture and transfection of siRNA in vitro PLC and HepG2 were obtained from the American Type Culture Collection (Rockville, MD, USA), Huh7 from Riken Cell Bank (Tsukuba, Ibaraki, Japan) deposited by Dr NamHo Huh and Huh1 from Health Science Research Resource Bank (Osaka, Japan). The cells were maintained in Dulbecco's modified eagle medium: nutrient mixture F-12 (DMEM/F12) media (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA, USA) at 37 1C in the presence of 5% CO 2. For the measurements of cell proliferation and apoptosis, cells were seeded at 25% confluence in 96-well plates 1 day before transfection in 100 ml of culture media without antibiotics. Lipofectamine 2000 was mixed with siRNA molecules in a volume of 50 ml Opti-MEM I (both from Invitrogen, Carlsbad, CA, USA) and added to HCC cells. The medium was replaced 24 h after transfection. The NCsiRNA were used in the same quantity and transfected to the cells simultaneously.
Measurement of cell proliferation and apoptotic cell death
The growth inhibitory effects of control and target siRNA were studied using the Vybrant MTT cell proliferation assay (Invitrogen) as recommended by the manufacturer. Absorbance was measured at 540 nm using an enzyme-linked immunosorbent assay (ELISA) reader SpectraMAX 190 (Molecular Devices, Sunnyvale, CA, USA). The percentage of viable cells was calculated by comparing the optical density using the following formula: (1Àabsorbance of an experimental well)/(absorbance of an untreated control well Â 100). The induction of apoptosis was measured using ApoStrand ELISA Apoptosis Detection kit (Biomol International, Plymouth Meeting, PA, USA).
Quantitative real-time (RT)-PCR
The changes in target gene expression on mRNA level were detected using real-time quantitative RT-PCR. Total RNA was isolated using Tri reagent (Molecular Research Center, Cincinnati, OH, USA) according to the protocol recommended by the manufacturer. A total of 1 mg of RNA was reverse transcribed using random primers supplied in the High-Capacity cDNA Archieve kit (Applied Biosystems, Carlsbad, CA, USA). cDNA of CSN5 gene was amplified using corresponding pair of primers (forward, 5 0 -TCTGCTGAAGATGGTGATGC-3 0 ; reverse, 5 0 -GC CAACCTGTTTTGCATTTT-3 0 ) synthesized by Operon Technology (Valencia, CA, USA), Power SYBR Green PCR Master Mix and ABI 7700HT PCR Machine (both from Applied Biosystems). The mRNA levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used for normalization. All reactions were performed in triplicate.
Western blot analysis
The amount of total protein was determined by BCA Protein Assay kit (Pierce, Rockford, IL, USA). A total of 100 mg of total protein were run using 4-20% sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred onto polyvinylidene fluoride (PVDF) membrane (Invitrogen). The membrane was blocked with 5% milk/tris-buffered saline plus Tween-20 and incubated with primary antibodies against human CSN3 (RR12), CSN5 (FL-334), CSN8 (C-19), Cullin 1 (H-213), p53 (FL-393), p27 (F-8), Myc (C-19), SKP2 (H-435), pSmad2/3 (SC-11769), NF-kB p65 (C-20), ITGB1 (M-106), CDK2 (M2), CDK6 (H-230), cyclin D1 (DCS-6), cyclin E (M-20), cyclin A (BF683), Bak (G-23), Bcl-2 (N-19) and Bcl-xL (H-5) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). CSN1 (#S0055) antibody was purchased from Epitomics (Burlingame, CA, USA) and Novus Biologics (Littleton, CO, USA), respectively. The antibodies against NEDD8 (#2745S) and caspase-3 (#9661) were available from Cell Signaling (Danvers, MA, USA). Immunoreactive bands were visualized using ECL Plus Western Blotting Detection System (GE Healthcare, Piscataway, NJ, USA). The equal loading was assessed by probing the same membrane with actin antibody (A1978, Sigma, St Louis, MO, USA).
Microarray analysis
Biotin-labeled cRNA was linearly amplified according to manufacturer's specification (AMIL1791; Ambion). As input, 200 ng total RNA were used for in vitro transcription reactions for 16 h at 37 1C. The efficiency of this single round amplification was measured by NanoDrop (ND1000, Thermo Scientific, Barrington, IL, USA). Hybridization, washing, detection (Cy3-streptavidin, Amersham Biosciences, GE Healthcare, Piscataway, NJ, USA) and scanning were performed on an Illumina iScan system (Illumina, San Diego, CA, USA) using reagents and following protocols supplied by the manufacturer. Briefly, the biotinylated cRNA (750 ng/sample) was hybridized on Sentrix whole genome beadchips human Ref-8v3 for 18 h at 58 1C, while rocking (5 r.p.m.). The beadchip covers B24 000 RefSeq transcripts. Image analysis and data extraction were performed automatically using Illumina GenomeScan Software. All microarray data were submitted to Gene Expression Omnibus database with the accession number of GSE26485.
Functional network analysis
To explore the functional relationships among the genes with altered expression in HCC cells treated with CSN5 siRNA, a pathway analysis was carried out using the Ingenuity Pathway Analysis tool (Ingenuity Systems, Redwood City, CA, USA). The significance of each network was estimated by scoring system provided by Ingenuity. The scores were determined by the number of differentially expressed genes within each network and the strength of the associations among the network members. Once over-represented and functionally relevant genes were identified, their functional association was validated by independent pathway analysis tool PathwayStudio (Ariadne Genomics, Rockville, MD, USA).
Generation of HCC reporter cell line expressing luciferase Huh7 cells were transfected with pGL4.17 vector (Promega, Madison, WI, USA) expressing firefly luciferase and neomycin resistance gene using Lipofectamine 2000. To enhance the expression of luciferase gene, b-actin promoter from pCAGEN plasmid (Addgene, Cambridge, MA, USA) was subcloned into multicloning site of pGL4.17. Cells were selected for antibiotic resistance with Geneticin (Invitrogen), and surviving colonies were amplified and screened for bioluminescence in complete media supplemented with 150 mg/ml D-luciferin (Biosynth International, Itasca, IL, USA) by in vitro imaging (IVIS Imaging System, Xenogen, Alameda, CA, USA). The Huh7-1H6 clone with a highest expression was selected and used throughout the study.
Systemic administration of SNALP-formulated siRNA and bioluminescence imaging in vivo Six-week-old male severe_combined_immuno-deficiency (SCID)/ Beige mice (Charles River Laboratories, Wilmington, MA, USA) were anesthetized by inhalation of 5% isoflorane in oxygen. Cells (5 Â 10 5 in 50 ml phosphate-buffered saline) were injected into the splenic pulp using a 27-gauge needle. Spleen was removed 30 s after injection and wound was closed in two layers using 3-0 silk suture and surgical clips. Body and liver weights were recorded at death. Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) facility and cared for in accordance with the guidelines from the Animal Care and Use Committee at the US National Cancer Institute, NIH. Mice with liver tumors derived from Huh7-luc þ cells were randomly assigned to treatment or control groups based on bioluminescence imaging before initiation of siRNA therapy. SNALP-formulated siRNAs (2 mg/kg) were injected into the lateral tail vein four times with a 3-day interval. Tumor growth was monitored by bioluminescence imaging for 4 weeks with 3-4 days intervals using an IVIS Imaging System. Images and measurements of luciferase signals were analyzed using Living Image Software (Xenogen); 10 min prior to in vivo imaging, mice were anesthesized with 1-3% isoflurane (Abbott Laboratories, Abbott Park, IL, USA) and given an i.p. injection luciferin (Biosynth International) at 150 mg/kg in DPBS. Regions of interest from displayed images were drawn around the tumor sites and quantified as photons/second using the software.
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